Skip to content

Study · Randomized controlled trial · n = 348 · 2007

8 results

Exenatide effects on statin pharmacokinetics and lipid response.

Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, Han J, Fineman M, Mitchell M

International journal of clinical pharmacology and therapeutics1 Feb 2007Cited by 29 (Europe PMC)

PMID17323791 (opens in a new tab)DOI10.5414/cpp45114 (opens in a new tab)PepBankPUB-17323791
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In statin-treated T2D patients, LDL cholesterol changes did not differ significantly between exenatide and placebo.

    In plain wordsLDL cholesterol changed similarly with exenatide and placebo in patients taking statins.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLDL cholesterol change
    Study

    n = 348

    Comparator
    Placebo with statins
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 microg twice daily · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    In the exenatide Phase 3 trials, 30-week changes from baseline for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides and statin dosage were not significantly different between the exenatide and placebo groups treated with statins.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In statin-treated T2D patients, HDL cholesterol changes did not differ significantly between exenatide and placebo.

    In plain wordsHDL cholesterol changed similarly with exenatide and placebo in patients taking statins.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHDL cholesterol change
    Study

    n = 348

    Comparator
    Placebo with statins
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 microg twice daily · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    In the exenatide Phase 3 trials, 30-week changes from baseline for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides and statin dosage were not significantly different between the exenatide and placebo groups treated with statins.
    1 context sentence
    Summary · context
    In a second clinical setting, changes in lipid profiles and statin dosage over 30 weeks in patients with type 2 diabetes were retrospectively compared (n = 180 exenatide 10 microg twice daily (BID), n = 168 placebo BID) in a combined analysis of three placebo-controlled, randomized exenatide Phase 3 trials.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In statin-treated T2D patients, total cholesterol changes did not differ significantly between exenatide and placebo.

    In plain wordsTotal cholesterol changed similarly with exenatide and placebo in patients taking statins.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTotal cholesterol change
    Study

    n = 348

    Comparator
    Placebo with statins
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 microg twice daily · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    In the exenatide Phase 3 trials, 30-week changes from baseline for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides and statin dosage were not significantly different between the exenatide and placebo groups treated with statins.
    1 context sentence
    Summary · context
    In a second clinical setting, changes in lipid profiles and statin dosage over 30 weeks in patients with type 2 diabetes were retrospectively compared (n = 180 exenatide 10 microg twice daily (BID), n = 168 placebo BID) in a combined analysis of three placebo-controlled, randomized exenatide Phase 3 trials.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In statin-treated T2D patients, triglyceride changes did not differ significantly between exenatide and placebo.

    In plain wordsTriglycerides changed similarly with exenatide and placebo in patients taking statins.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTriglyceride change
    Study

    n = 348

    Comparator
    Placebo with statins
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 microg twice daily · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    In the exenatide Phase 3 trials, 30-week changes from baseline for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides and statin dosage were not significantly different between the exenatide and placebo groups treated with statins.
    1 context sentence
    Summary · context
    In a second clinical setting, changes in lipid profiles and statin dosage over 30 weeks in patients with type 2 diabetes were retrospectively compared (n = 180 exenatide 10 microg twice daily (BID), n = 168 placebo BID) in a combined analysis of three placebo-controlled, randomized exenatide Phase 3 trials.
  5. 05HumanRandomized controlled trialOther

    In statin-treated T2D patients, statin dosage changes did not differ significantly between exenatide and placebo.

    In plain wordsStatin doses changed similarly with exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeStatin dosage change
    Study

    n = 348

    Comparator
    Placebo with statins
    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    10 microg twice daily · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    In the exenatide Phase 3 trials, 30-week changes from baseline for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides and statin dosage were not significantly different between the exenatide and placebo groups treated with statins.
    1 context sentence
    Summary · context
    In a second clinical setting, changes in lipid profiles and statin dosage over 30 weeks in patients with type 2 diabetes were retrospectively compared (n = 180 exenatide 10 microg twice daily (BID), n = 168 placebo BID) in a combined analysis of three placebo-controlled, randomized exenatide Phase 3 trials.
  6. 06HumanNon-randomized trialPharmacokinetics

    In healthy subjects, exenatide reduced lovastatin exposure versus lovastatin alone.

    In plain wordsExenatide reduced overall lovastatin exposure compared with lovastatin alone in healthy people.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLovastatin exposure
    Study

    n = 21

    Comparator
    Lovastatin without exenatide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg before breakfast and dinnerAs given in this study (human).

    Measurements

    Lovastatin AUC reduction
    40%
    exenatide

    Source sentences

    Summary
    In healthy subjects, exenatide decreased mean lovastatin area under the plasma concentration time curve from zero to infinity (AUC0-infinity) and maximum plasma concentration (Cmax) by 40 and 28%, respectively, and increased median time to maximum plasma concentration (tmax) by 4 hours.
    1 context sentence
    Summary · context
    In an open-label, fixed-sequence, clinical pharmacology study, the plasma pharmacokinetics of lovastatin (40 mg after breakfast) in the presence and absence of exenatide (10 microg before breakfast and dinner) was evaluated in 21 healthy subjects.
  7. 07HumanNon-randomized trialPharmacokinetics

    In healthy subjects, exenatide reduced lovastatin peak concentration versus lovastatin alone.

    In plain wordsExenatide reduced peak lovastatin levels compared with lovastatin alone in healthy people.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLovastatin maximum concentration
    Study

    n = 21

    Comparator
    Lovastatin without exenatide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg before breakfast and dinnerAs given in this study (human).

    Measurements

    Lovastatin Cmax reduction
    28%
    exenatide

    Source sentences

    Summary
    In healthy subjects, exenatide decreased mean lovastatin area under the plasma concentration time curve from zero to infinity (AUC0-infinity) and maximum plasma concentration (Cmax) by 40 and 28%, respectively, and increased median time to maximum plasma concentration (tmax) by 4 hours.
    1 context sentence
    Summary · context
    In an open-label, fixed-sequence, clinical pharmacology study, the plasma pharmacokinetics of lovastatin (40 mg after breakfast) in the presence and absence of exenatide (10 microg before breakfast and dinner) was evaluated in 21 healthy subjects.
  8. 08HumanNon-randomized trialPharmacokinetics

    In healthy subjects, exenatide delayed lovastatin peak concentration versus lovastatin alone.

    In plain wordsExenatide delayed peak lovastatin levels compared with lovastatin alone in healthy people.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLovastatin time to maximum concentration
    Study

    n = 21

    Comparator
    Lovastatin without exenatide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg before breakfast and dinnerAs given in this study (human).

    Measurements

    Lovastatin tmax increase
    4 hours
    exenatide

    Source sentences

    Summary
    In healthy subjects, exenatide decreased mean lovastatin area under the plasma concentration time curve from zero to infinity (AUC0-infinity) and maximum plasma concentration (Cmax) by 40 and 28%, respectively, and increased median time to maximum plasma concentration (tmax) by 4 hours.
    1 context sentence
    Summary · context
    In an open-label, fixed-sequence, clinical pharmacology study, the plasma pharmacokinetics of lovastatin (40 mg after breakfast) in the presence and absence of exenatide (10 microg before breakfast and dinner) was evaluated in 21 healthy subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.